Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CAR-T Followed by Allo-SCT in Refractory B-lineage Leukemia/Lymphoma
NCT03110640Phase 1Unknown
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Oct 2016
- Primary completion
- Jun 2020
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous anti-CD19 CAR-T cells in B cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL) and B cell lymphoma, sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoint: Dose-Limited Toxicity at 180 days. Status: unknown.
02
Drugs
autologous anti-CD19 CAR-T cells
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)chronic lymphocytic leukemia (CLL)B cell lymphoma
Beyond the preview
Go deeper on NCT03110640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03110640.